Profit warning pummels Lunar's stock
Shares of bone densitometry vendor Lunar plunged on Sept. 22 after the Madison, WI, company announced that it expected to post flat revenues and lower profits for its first fiscal quarter (end-September). The results were due to lower-than-expected
Shares of bone densitometry vendor Lunar plunged on Sept. 22 after the Madison, WI, company announced that it expected to post flat revenues and lower profits for its first fiscal quarter (end-September). The results were due to lower-than-expected densitometry sales in Japan and in the U.S., where many physicians have been confused about proposed reductions in the Medicare reimbursement rate for bone densitometry, according to the company. Lunar's stock dropped $4.56 a share, or 19%, to close at $19.44 on Sept. 22, the first day of trading after the news was announced.
In other Lunar news, the company in early September began shipping Pixi, its compact dual-energy x-ray absorptiometry (DEXA) densitometer. Pixi is targeted at the physician-office market and carries a list price of $32,000. Lunar shipped the first Pixi unit to a physician in the Washington, DC, area, according to the company.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
